ARPE-19 cells were obtained from ATCC (Manassas, VA). Cells were grown in a 1:1 mixture (vol/vol) of Dulbecco modified Eagle and Ham nutrient mixture F-12 medium (DMEM F-12; Invitrogen-Gibco, Carlsbad, CA), nonessential amino acids 10 mM 1×, 0.37% sodium bicarbonate, 0.058% l-glutamine, 10% fetal bovine serum, and antibiotics (penicillin G 100 U/mL, streptomycin sulfate 0.1 mg/mL, gentamicin 10 μg/mL, amphotericin B 2.5 μg/mL). Cells were plated in 6- and 24-well plates (Becton Dickinson Labware, Franklin Lakes, NJ) for cell viability (5.5 × 105 cells/well) and caspase (1.5 × 105 cells/well) assays. When ARPE-19 cells became confluent, they were incubated for 24 hours in serum-free medium so that they would be relatively nonproliferating. This simulated the natural human RPE cells, which remained in a nonproliferating phase and which were not exposed to the circulation because of the blood-retinal barrier. The cells were exposed to B(e)P. Passage numbers 12 to 15 were used for the experiments. Keeping in mind the fact that enzyme activity levels can vary with time, experiments were performed in triplicate, and the entire experiment was repeated three different times. Then the values were combined and calculated statistically to show a consistent increase of caspase activity.